.Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B06A_OtherHematologicalAgents.B06AX01_Crizanlizumab.Crizanlizumab .Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B06A_OtherHematologicalAgents.B06AX01_Crizanlizumab.Crizanlizumab| name: | Crizanlizumab |
| ATC code: | B06AX01 | route: | intravenous |
| n-compartments | 2 |
Crizanlizumab is a humanized monoclonal antibody that binds to P-selectin, a cell adhesion molecule expressed on the surface of activated endothelial cells and platelets. It is approved for the prevention of vaso-occlusive crises in patients with sickle cell disease.
Pharmacokinetic parameters as reported in adults with sickle cell disease. The parameters represent population PK analysis in clinical trial participants.
Sy, SKB, et al., & Grosch, K (2023). Population Pharmacokinetics and Pharmacodynamics of Crizanlizumab in Healthy Subjects and Patients with Sickle Cell Disease. Clinical pharmacokinetics 62(2) 249–266. DOI:10.1007/s40262-022-01193-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36529836